TAGE (toxic AGEs) hypothesis in various chronic diseases
Tóm tắt
Từ khóa
Tài liệu tham khảo
Yamagishi, 2002, Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes, Biochem. Biophys. Res. Commun., 290, 973, 10.1006/bbrc.2001.6312
Okamoto, 2002, Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin, FASEB J., 16, 1928, 10.1096/fj.02-0030fje
Takeuchi, 2000, Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo, Mol. Med., 6, 114, 10.1007/BF03401779
Takeuchi, 2001, Immunological detection of a novel advanced glycation end-product, Mol. Med., 7, 783, 10.1007/BF03401969
Koga, 2002, Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction, Int. J. Clin. Pharm. Res., 22, 23
Yamagishi, 2002, Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human cultured mesangial cells, J. Biol. Chem., 277, 20309, 10.1074/jbc.M202634200
Nakamura, 1997, Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation, Diabetes, 46, 895, 10.2337/diab.46.5.895
Tsuchida, 1999, Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195, Diabetologia, 42, 579, 10.1007/s001250051198
Yamagishi, 2003, Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells, Kidney. Int., 63, 464, 10.1046/j.1523-1755.2003.00752.x
Wada, 2001, Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy, Eur. J. Clin. Invest, 31, 513, 10.1046/j.1365-2362.2001.00826.x
Sasaki, 2001, Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease, Brain Res., 888, 256, 10.1016/S0006-8993(00)03075-4
Takeuchi, 1999, Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients, Mol. Med., 5, 393, 10.1007/BF03402128
Takeuchi, 2001, Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo, Curr. Mol. Med., 1, 305, 10.2174/1566524013363735
Takeuchi, 2000, Neurotoxicity of advanced glycation end-products for cultured cortical neurons, J. Neuropathol. Exp. Neurol., 59, 1094, 10.1093/jnen/59.12.1094
Takeuchi, 2004, Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease, Curr Alzheimer Res, 1, 39, 10.2174/1567205043480582
Abe, 2004, Regulation of human malignant melanoma growth and metastasis by AGE-AGE receptor interactions, J Invest Dermatol, 122, 461, 10.1046/j.0022-202X.2004.22218.x
Yonekura, 2002, RAGE engagement and vascular cell derangement by short chain sugar-derived advanced glycation end products, vol. 1245, 129
Al-Abed, 1999, Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol, Proc. Natl. Acad. Sci. USA, 96, 2385, 10.1073/pnas.96.5.2385